Latest Breaking News On - Sciences group inc - Page 2 : comparemela.com

SELLAS Life Sciences Group Inc (NASDAQ: SLS) released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S (GPS), combined with Bristol Myers Squibb Co (NYSE: BMY) nivolumab (Opdivo) in patients with malignant pleural mesothelioma (MPM) who were either refractory to or relapsed after at least one line of the standard of care therapy. Pleural mesothelioma (a lining that protects internal organs) is cancer that forms in the tissues covering the lungs and chest wall. Nin

Bristol myers squibb coSellas life sciences group incSciences group incBenzinga proSurvival rates improveSevere lung cancerMalignant pleural mesotheliomaInternal organs